Background {#Sec1}
==========

A hepatic sclerosed hemangioma (HSH) is a very rare benign subtype of hepatic hemangioma and is detected in only 0.2% of cases in a study of 1000 consecutive necropsies \[[@CR1]\]. Since its image features resemble those of hepatic malignancies such as intrahepatic cholangiocarcinoma (ICC) \[[@CR2]\] or colorectal liver metastasis (CRLM) \[[@CR3]\], HSH is frequently suspected to be hepatic malignancies that need to be resected. Overall, HSH is often diagnosed correctly after resection. To avoid an unnecessary operation, accurate preoperative diagnosis of HSH is required.

One of the most effective methods for the differential diagnosis of liver tumors is magnetic resonance imaging (MRI). Conventional and diffusion-weighted MRI (DW-MRI) are effective techniques for the characterization of focal solid hepatic lesions \[[@CR4]\]. In addition, the apparent diffusion coefficient (ADC) value in DW-MRI has been useful for distinguishing malignant from benign liver tumors \[[@CR4]--[@CR6]\]. To the best of our knowledge, this is the first study about the utility of the ADC mean (ADC~mean~) value in multiple patients with HSH. We herein would like to demonstrate detailed imaging findings of five cases along with literature reviews.

Cases presentation {#Sec2}
==================

Patients and imaging methods {#Sec3}
----------------------------

From July 2009 to November 2016, five patients in our institutions were histologically diagnosed using a resected specimen with HSH, which were confirmed by pathologists. The patients underwent imaging examinations, including ultrasonography (US), contrast-enhanced computed tomography (CT), gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI, and ^18^F-fluorodeoxyglucose positron-emission tomography (FDG-PET). We considered the part with the contrast effect in CT as non-degenerative site, and the other part as degenerative site. To obtain an accurate preoperative diagnosis, we additionally performed DW-MRI with respiratory triggering using *b* values of 0 and 800 s/mm^2^, and ADC maps were generated using *b* values of 0 and 800 s/mm^2^ for calculation of the ADC value. Of the five patients, four were evaluated using a 3.0-Tesla whole-body MRI scanner and one patient was evaluated using a 1.5-Tesla whole-body MRI scanner; studies have demonstrated similar ADC values between the 1.5- and 3.0-Tesla scanners \[[@CR7], [@CR8]\]. The ADC~mean~ value was calculated by taking the average of the six areas of ADC values, which were randomly selected at the degenerative (three areas) and non-degenerative areas (three areas) of each HSH. Similarly, we separately evaluated the ADC~mean~ values in the degenerative and non-degenerative areas. For the comparative analysis, we also evaluated the ADC~mean~ values in the degenerative and non-degenerative areas of the adenocarcinoma with necrosis in the liver. We randomly selected six ICC patients and four CRLM patients from our database of patients with liver tumors. They were also diagnosed histologically using the resected specimen. The radiological data was independently assessed by two radiologists. We also retrospectively investigated the preoperative blood test data, imaging data, and pathological findings.

Statistical analysis {#Sec4}
--------------------

Comparisons between the ADC~mean~ values of the degenerative and non-degenerative areas were examined using Student's *t* test. The results with two-tailed values of *P* \< 0.05 were considered to be statistically significant. All statistical analyses were performed using JMP software (Version 12; SAS Institute, Cary, NC, USA).

Patient characteristics {#Sec5}
-----------------------

The clinical characteristics of the patients with HSH were summarized in Table [1](#Tab1){ref-type="table"}. Four male and one female were included, and their mean age was 60 years (range 34--79 years). Hepatitis B virus surface antigen (HBs-Ag) was positive in two patients, and hepatitis C virus antibody (HCV-Ab) was negative in all patients. All patients' carcinoembryonic antigen and carbohydrate antigen 19--9 were within their normal ranges. The most predicted preoperative diagnoses were HSH in two patients, cavernous hemangioma in one, ICC in one, and CRLM in one.Table 1Characteristics of five patients with hepatic sclerosed hemangiomaCaseAgeGenderEtiologyCA19-9 (U/ml)CEA (ng/ml)ComorbidityLocationSize (mm)Preoperative diagnosisOperationCase 179MNone8.51.0NoneS5/643ICCAnatomical resectionCase 234FNone161.1NoneWhole right lobe148HemangiomaExtended hemi-right hepatectomyCase 370MHBV6.42.5Colon cancerS615CRLMLaparoscopic partial hepatectomyCase 463MHBV12.71.7HCC (S4)S76Sclerosed hemangiomaPartial hepatectomyCase 554MNone9.11.4NoneS827Sclerosed hemangiomaPartial hepatectomy*HBV* hepatic B virus, *CA19-9* carbohydrate antigen 19-9, *CEA* carcinoembryonic antigen, *ICC* intrahepatic cholangiocarcinoma, *CRLM* colorectal liver metastasis

US, CT, and PET imaging features {#Sec6}
--------------------------------

HSH presented with different echogenicity based on the degree of regenerative tissue in the ultrasound images. The features of HSH on CT were summarized in Table [2](#Tab2){ref-type="table"}. All tumors were solitary with lobulated shapes, and the tumor sizes varied from 6 to 148 mm. Three patients had simultaneous hemangiomas, and three patients showed contractive changes on the tumor surface. All tumors had low densities on plain CT images. Two patients had ring enhancements, and two patients had peripheral nodular enhancements in the arterial phase. Two tumors had a low-density mass, and three had a progressive centripetal fill-in pattern from the portal to venous phase in the CT images (as seen in cases 3 and 5 shown in Figs. [1a](#Fig1){ref-type="fig"} and [2a](#Fig2){ref-type="fig"}). Three patients underwent FDG-PET; however, no FDG accumulation was observed in the HSH.Table 2Computed tomography (CT) features of five patients with hepatic sclerosed hemangiomaDynamic CTCaseSimultaneous hemangiomaCapsular retractionArterioportal shuntPlain CTArterial phasePortal phaseVenous phaseCase 1+−+LowRing enhancementProgressive centripetal fill-inProgressive centripetal fill-inCase 2−−−LowPeripheral nodular enhancementProgressive centripetal fill-inProgressive centripetal fill-inCase 3++−LowRing enhancementLowLowCase 4−++LowLowLowLowCase 5+++LowPeripheral nodular enhancementProgressive centripetal fill-inLowFig. 1The tumor showed ring enhancement in the arterial phase and low-density mass in the portal phase (**a**) in a CT image. MRI showed that HSH is a hypointense mass on a fat-suppressed T1-weighted image and a hyperintense mass on a T2-weighted MRI scan (**b**). The ADC~mean~ value of the mass was 2.10 × 10^−3^ mm^2^/s on DW-MRI (**c**). A whitish tumor was shown on the liver surface and capsular retraction was identified (**d**). Histologically, there were many small vessels with fibrous replacement and hyalinization (**e**)Fig. 2The tumor was seen as a mass with peripheral nodular enhancement in the arterial phase and progressive centripetal fill-in in the portal phase of CT imaging (**a**). MRI showed that HSH was a hypointense mass on a fat-suppressed T1-weighted image and a mass with peripheral nodular enhancement in the early phase. In the late phase, the tumor was an iso-hypointense mass and filling defect in the hepatocyte phase of dynamic MRI. We considered the part with the contrast effect in CT or MRI as non-degenerative site (arrow) and the other part as degenerative site (arrow head). (**b**). The ADC~mean~ value of the mass was 2.09 × 10^−3^ mm^2^/s on DW-MRI (**c**). The whitish part was shown within the hemangioma-like tumor on the liver surface and capsular retraction was identified (**d**). Histologically, there were many small vessels with fibrous replacement and hyalinization. The scale bar shows 1.0 mm (**e**)

MRI features {#Sec7}
------------

The features of HSH on MRI were summarized in Table [3](#Tab3){ref-type="table"}. All tumors had no fatty tissue and were hypointense on T1-weighted images and hyperintense on T2-weighted images, as seen in case 3 (Fig. [1](#Fig1){ref-type="fig"}b). Three tumors showed ring enhancements, and two tumors showed peripheral nodular enhancements in the arterial phase. Three tumors showed progressive centripetal fill-in patterns during the late phase. All tumors were described as defects in the hepatocyte phase on MRI, as seen in case 5 (Fig. [2](#Fig2){ref-type="fig"}b). The average ADC~mean~ value for the five cases was 1.94 × 10^−3^ mm^2^/s (range 1.72--2.09 × 10^−3^ mm^2^/s). The average (± standard deviation) values of the ADC~mean~ were approximately the same between the degenerate (1.90 ± 0.17 × 10^−3^ mm^2^/s) and non-degenerate areas (1.95 ± 0.26 × 10^−3^ mm^2^/s; *p* = 0.615) (Fig. [3](#Fig3){ref-type="fig"}). However, there were significant differences in the ADC~mean~ values between the enhanced (1.90 ± 0.25 × 10^−3^ mm^2^/s) and non-enhanced areas (1.18 ± 0.25 × 10^−3^ mm^2^/s) of ICC and CRLM in the early phase of MRI (*p* \< 0.0001) (Fig. [4](#Fig4){ref-type="fig"}). Their background factors were listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1.Table 3Magnetic resonance imaging (MRI) features of five patients with hepatic sclerosed hemangiomaCaseBorderFatty tissueT1-weighted T2-weightedDynamic MRI findingsADC mean (×10^--3^ mm^2^/s)Fat-suppressed T1-weightedEarly phaseLate phaseHepatocyte phaseDegenerative areaNon-degenerative areaCase 1Lobulated shape--Hypo\
HyperHypoRing enhancementProgressive centripetal fill-inDefect1.651.801.561.611.752.00Case 2Lobulated shape--Hypo\
HyperHypoPeripheral nodular enhancementProgressive centripetal fill-inDefect1.871.801.801.861.931.72Case 3Lobulated shape--Hypo\
HyperHypoRing enhancementProgressive centripetal fill-inDefect2.07--2.162.09Case 4Lobulated shape--Hypo\
HyperHypoRing enhancementHypoDefect2.00--1.931.96Case 5\*Lobulated shape--Hypo\
HyperHypoPeripheral nodular enhancementIso-hypoDefect1.942.231.952.121.902.38*ADC* apparent diffusion coefficient, *Hypo* hypo intensity, *Hyper* hyper intensity\*The results were obtained using 1.5-tesla MRIFig. 3The average values of ADC~mean~ were almost the same between the degenerate (1.90 ± 0.17 × 10^−3^ mm^2^/s) and the non-degenerate areas (1.95 ± 0.26 × 10^−3^ mm^2^/s) (*t* test, *p* = 0.615). ^※^Two cases were very small tumors; therefore, we could not determine the ADC~mean~ value in the non-degenerative areaFig. 4The average values of ADC~mean~ in six ICCs (18 area) and four CRLMs (12 area) were significantly different between the degenerate and the non-degenerate areas (*t* test, *p* \< 0.0001). Asterisk denotes *p* \< 0.0001

Operation and pathological examination {#Sec8}
--------------------------------------

Although three patients were diagnosed with suspicious benign tumors, we could not deny their possibility of malignancy. Furthermore, patients desired to receive hepatectomy to obtain pathological diagnosis. We underwent laparoscopic hepatectomy for one (case 3) and hepatectomy with laparotomy for the others (Table [1](#Tab1){ref-type="table"}). Histologically, there were many small vessels with fibrous replacement and hyalinization in all cases. All patients could discharge without any complications.

Discussion {#Sec9}
==========

Herein, we described the clinical, pathological, and imaging features of five patients with HSH. Interestingly, the ADC~mean~ values had a different pattern between HSH and malignant liver metastases; however, the ADC~mean~ values were similar in the degenerate and non-degenerate areas of HSH. To the best of our knowledge, the current study is the first report to mention the differences of ADC~mean~ values between the degenerate and non-degenerate areas in HSH.

Cavernous hemangioma is the most common hepatic vascular tumor in adults \[[@CR9]\], while HSH is an extremely rare liver tumor \[[@CR1]\]. HSH has various degenerative changes such as extensive fibrosis with subsequent hyalinization, marked narrowing or obliteration of the vascular spaces, and hemorrhage or sclerosis \[[@CR10]\]. Makhlouf and Ishak compared the findings of HSH and cavernous hemangioma in terms of pathology. Compared with cavernous hemangioma, HSH contained abundance of collagenous tissue and elastic fibers around and between small sclerotic vessels. In addition, vascular endothelial markers (i.e., CD31, CD34, FVIII-R Ag) were weaker, suggesting there was senescence in blood vessels \[[@CR11]\]. However, the mechanism for degenerative changes in HSH and the origin of HSH remain unclear at present. HSH itself is benign tumor; therefore, it is considered good to follow up without resection as long as there are no symptoms.

Cavernous hemangioma is usually found as a single mass tumor of five cm or less \[[@CR12]\]. It is contrasted from the periphery in dynamic CT, the contrast effect gradually spreads to the center (progressive centripetal fill-in), and furthermore, the contrast effect prolonging from the equilibrium phase to the delay phase (prolonged enhancement) is recognized \[[@CR13]\]. On the other hand, HSH has several different imaging features. Doyle et al. reported that the findings of geographic pattern, capsular retraction, decreased size over time, and loss of previously seen regions of enhancement suggested HSH. Moreover, they also showed a difference in the transient hepatic attenuation, rim enhancement, and nodular regions of intense enhancement, as seen in typical hemangiomas \[[@CR14]\]. In our cases, all tumors showed ring enhancement or peripheral nodular enhancement in the arterial phase and two cases were described as having progressive centripetal fill-in from the portal to the venous phase in CT images. Therefore, all cases had previous features of HSH or cavernous hemangioma; however, we could not deny the possibility of a malignancy because ICC and CRLM have several similar features on imaging \[[@CR2], [@CR3]\]. In particular, in case 3, the patient was simultaneously diagnosed with colon cancer, which contributed to a misdiagnosis of the liver tumor as CRLM. Sakamoto et al. reported that liver hemangioma of 5 cm or less was frequently diagnosed as malignant tumor \[[@CR15]\], and even in our cases, four cases were HSH of 5 cm or less. Thus, it is quite difficult to perform accurate diagnosis only with dynamic CT or MRI.

The ADC~mean~ value on DW-MRI may be useful for distinguishing HSH from other malignant liver tumors. In malignant tumors, we often observed tissue invasion and a cancerous environment with increased cellularity and enlarged cells, which contributed to a reduction in the extracellular space. In addition, cancer cells harbored more hyperchromatin and exhibited a high nucleus-to-cytoplasm ratio, limiting the diffusion of water molecules in intracellular spaces \[[@CR4], [@CR5]\]. These histopathological characteristics result in a decrease in the ADC~mean~ value. Bruegel et al. showed that the ADC~mean~ value was 1.22 × 10^−3^ mm^2^/s for metastatic liver tumors and 1.92 × 10^−3^ mm^2^/s for hemangiomas \[[@CR16]\]. Namimoto et al. also showed that the ADC~mean~ values of the hepatocellular carcinoma, metastases, ICC, and hemangiomas were 1.15 ± 0.21 × 10^−3^, 1.23 ± 0.32 × 10^−3^, 1.52 ± 0.26 × 10^−3^, and 2.09 ± 0.43 × 10^−3^ mm^2^/s, respectively \[[@CR5]\]. In addition, Hida et al. showed that the ADC~mean~ value of HSH was 2.01 × 10^−3^ mm^2^/s \[[@CR17]\]. Therefore, these authors suggested that the ADC~mean~ values of HSH and cavernous hemangioma (approximately 2.00 × 10^−3^ mm^2^/s) tended to be higher than those of malignant liver tumors. In our five cases, the average ADC~mean~ value of the five HSHs was 1.94 × 10 × 10^−3^ mm^2^/s. This result support previous reports.

Interestingly, our results also showed the ADC~mean~ values were almost of the same degree and higher than malignant tumors between the degenerate and the non-degenerate areas, suggesting that the non-degenerate areas had a similar cellular density compared to the degenerate areas in HSH. In fact, in the pathological findings, although the fibrous tissue of the degenerate area was abundant, the cell density in the degenerate area was not very high. In addition, it is recognized that the size of HSH decreases; it is rare to limit the extracellular space. On the other hand, in the case of a malignant tumor, tissue invasion and cancer nests exhibiting increased cellularity and enlarged cells. This reduced the size of the extracellular space, and the cancer cells harbored more organelles, enlarged nuclei, and hyperchromatism and exhibited a high nuclear-to-cytoplasmic ratio, limiting the diffusion of water molecules in intracellular spaces \[[@CR5]\]. Therefore, there is a difference in the ADC value between the contrast part and the non-contrast part in malignant tumor. Thus, our data suggested that it was possible to distinguish between HSH and malignant liver tumors by calculating the ADC~mean~ values in tumor and by comparing both the degenerate and non-degenerate areas in HSH.

Conclusions {#Sec10}
===========

Using the ADC~mean~ value on DW-MRI may be an effective method for distinguishing HSHs from other malignant liver tumors, especially in liver adenocarcinomas with degenerative areas. Further investigation of a large number of HSH patients will be needed.

Additional file {#Sec11}
===============

Additional file 1: Table S1.Characteristics of patients with ICC or CRLM. (DOCX 142 kb)

ADC

:   Apparent diffusion coefficient

CRLM

:   Colorectal liver metastasis

CT

:   Computed tomography

FDG-PET

:   Fluorodeoxyglucose positron-emission tomography

Gd-EOB-DTPA

:   Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid

HSH

:   Hepatic sclerosed hemangioma

ICC

:   Intrahepatic cholangiocarcinoma

MRI

:   Magnetic resonance imaging

US

:   Ultrasonography
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